公开(公告)号：US08822705B2

公开(公告)日：2014-09-02

申请号：US12362938

申请日：2009-01-30

申请人： Je-Tae Woo ,  Masato Ohta ,  Takayuki Yonezama ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai ,  Toshihiro Akihisa ,  Hiroyuki Akazawa

发明人： Je-Tae Woo ,  Masato Ohta ,  Takayuki Yonezama ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai ,  Toshihiro Akihisa ,  Hiroyuki Akazawa

IPC分类号： C07H15/24 ,  C07H15/26 ,  A61K31/7048 ,  A61K31/335 ,  C07D313/00

CPC分类号： C07D313/00 ,  A23L33/10 ,  A23V2002/00 ,  A61K31/05 ,  A61K31/065 ,  A61K31/335 ,  A61K31/7048 ,  A61K36/18 ,  C07H15/24 ,  C07H15/26 ,  C07H17/08 ,  A23V2200/30 ,  A23V2200/312 ,  A23V2250/21 ,  A23V2200/306

摘要： The present invention provides a highly safe pharmaceutical composition for preventing and/or treating bone disease, a pharmaceutical preparation comprising thereof, a health food comprising thereof, a functional food comprising thereof. Since the present invention comprises the arylheptanoid compound shown in the following formula (I) and the derivatives thereof, it enables to prevent and/or treat the bone disease. (In the formula (I), R1 and R5 are a functional group selected from the group consisting of a hydrogen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R2, R3, and R4 are a functional group selected from the group consisting of a hydrogen atom, an oxygen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R5 may be bound on meta-position against heptylene group of another aryl group to form a ring.)

摘要翻译： 本发明提供了用于预防和/或治疗骨疾病的高度安全的药物组合物，包含其的药物制剂，包含其的保健食品，由其组成的功能性食品。 由于本发明包括下式（I）所示的芳基庚类化合物及其衍生物，因此能够预防和/或治疗骨病。 （式（I）中，R 1和R 5为选自氢原子，碳原子数1〜3的烷基，单糖和二糖的官能团; R2，R3，R4为选自 由氢原子，氧原子，碳数为1〜3的烷基，单糖和二糖组成的组; R5可以与另一个芳基的亚庚基的间位结合形成环。）

公开(公告)号：US20130102796A1

公开(公告)日：2013-04-25

申请号：US13581975

申请日：2011-02-28

申请人： Je-Tae Woo ,  Ayaka Hibino ,  Takayuki Yonezawa ,  Midori Asai ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai

发明人： Je-Tae Woo ,  Ayaka Hibino ,  Takayuki Yonezawa ,  Midori Asai ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai

IPC分类号： A61K31/353

CPC分类号： A61K31/353 ,  A61K31/352 ,  C07D311/16 ,  C07D311/18 ,  Y02A50/409

摘要： Agents or pharmaceutical compositions for promoting osteoblast differentiation include purified auraptene or coumarin analogs thereof represented by the following formula 1: wherein R1 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, or a carboxyethyl; R2 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, a carboxyethyl or a coumarinyl; R3 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl or a carboxyethyl; and R4 represents a hydrogen, a C1-C15 liner or branched alkyl, an alkenyl, an alkadienyl or an alkatrienyl.

摘要翻译： 用于促进成骨细胞分化的试剂或药物组合物包括由下式1表示的纯化的紫罗烯或其香豆素类似物：其中R 1表示氢，羟基，甲氧基，甲基，乙基，丙基，羧基，羧甲基或 羧乙基; R 2表示氢，羟基，甲氧基，甲基，乙基，丙基，羧基，羧甲基，羧基乙基或香豆素基; R3表示氢，羟基，甲氧基，甲基，乙基，丙基，羧基，羧甲基或羧基乙基; 并且R 4表示氢，C 1 -C 15内衬或支链烷基，烯基，链二烯基或链亚三烯基。

公开(公告)号：US20070232703A1

公开(公告)日：2007-10-04

申请号：US11708041

申请日：2007-02-20

申请人： Kun-Hyung Lee ,  Byung-Yoon Cha ,  Takayuki Yonezawa ,  Shinichi Hasegawa ,  Je-Tae Woo ,  Kazuo Nagai

发明人： Kun-Hyung Lee ,  Byung-Yoon Cha ,  Takayuki Yonezawa ,  Shinichi Hasegawa ,  Je-Tae Woo ,  Kazuo Nagai

IPC分类号： A61K31/05 ,  A61K31/075

CPC分类号： A61K31/075 ,  A23L33/10 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/05 ,  A23V2200/306 ,  A23V2250/21

摘要： The present invention provides the pharmaceutical compositions, the pharmaceutical preparations thereof as an active ingredient, the health food, the food with health-promoting benefits and the like. The present invention provides the above-mentioned pharmaceutical preparations and the like comprising at least one of the compound shown in the following formula (I), physiologically acceptable salt thereof, or hydrate thereof. (wherein, R′1, R′2, and R′3 are independently a hydrogen atom, OH, or alkoxy group having C1 to C3, respectively. R1, R2, and R3 are independently a hydrogen atom or alkenyl group having C3 to C5, respectively).

摘要翻译： 本发明提供作为活性成分的药物组合物，其药物制剂，保健食品，具有促进健康益处的食品等。 本发明提供了包含下式（I）所示的化合物，其生理学上可接受的盐或其水合物中的至少一种的上述药物制剂等。 （其中R'1，R'2和R 3'独立地是氢原子，OH或具有C 1〜 R 1，R 2，R 3和R 3分别独立地为氢原子或具有C 3至C 5的烯基）。

公开(公告)号：US20120196927A1

公开(公告)日：2012-08-02

申请号：US13296356

申请日：2011-11-15

申请人： Young-Sil Lee ,  Byung-Yoon Cha ,  Xiao-Xing Wang ,  Sun-Sil Choi ,  Bong-Keun Choi ,  Hiroshi Yamakawa ,  Kiyoto Saito ,  Takayuki Yonezawa ,  Toshiaki Teruya ,  Kazuo Nagai ,  Je-Tae Woo

发明人： Young-Sil Lee ,  Byung-Yoon Cha ,  Xiao-Xing Wang ,  Sun-Sil Choi ,  Bong-Keun Choi ,  Hiroshi Yamakawa ,  Kiyoto Saito ,  Takayuki Yonezawa ,  Toshiaki Teruya ,  Kazuo Nagai ,  Je-Tae Woo

IPC分类号： A61K31/353 ,  C12Q1/68 ,  G01N21/64 ,  A61P3/00

CPC分类号： A61K31/352 ,  A23L33/105 ,  A23L33/30 ,  A23V2002/00 ,  A61K36/752 ,  C12Q1/6883 ,  C12Q2600/136 ,  G01N2500/00 ,  A23V2200/328 ,  A23V2200/332 ,  A23V2250/20

摘要： A method for screening a substance for treating visceral adiposity syndrome comprises: (1) extracting a total RNA fraction from skeletal muscle collected from non-human mammals of a group to which a predetermined amount of the test substance has been administered and from non-human mammals of a group to which the test substance has not been administered; (2) quantifying the expression quantity of mRNA in the total RNA fraction extracted that encodes a glucose transporter gene by a specific method; and (3) comparing and analyzing the quantity of the test substance ingested, the body weight gain, and the expression quantity of RNA encoding the glucose transporter gene during the administration period for the non-human mammals of the test substance-administered group to these quantities for the non-human mammals that constitute the test substance-unadministered group to thereby determine the effect of the test substance on the metabolic syndrome.

摘要翻译： 用于筛选用于治疗内脏肥胖症综合征的物质的方法包括：（1）从已经给予预定量的测试物质的组的非人哺乳动物收集的骨骼肌中提取总RNA级分，并从非人类 被检物质未经施用的群体的哺乳动物; （2）通过具体方法定量提取的编码葡萄糖转运蛋白基因的总RNA级分中mRNA的表达量; 和（3）比较和分析所测试物质给药组的非人哺乳动物在给药期间所摄入的测试物质的数量，体重增加和编码葡萄糖转运蛋白基因的RNA的表达量 构成被检物质的非人类哺乳动物的数量 - 未施用组，从而确定测试物质对代谢综合征的影响。

公开(公告)号：US20090227527A1

公开(公告)日：2009-09-10

申请号：US12362938

申请日：2009-01-30

申请人： Je-Tae Woo ,  Masato Ohta ,  Takayuki Yonezama ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai ,  Toshihiro Akihisa ,  Hiroyuki Akazawa

发明人： Je-Tae Woo ,  Masato Ohta ,  Takayuki Yonezama ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai ,  Toshihiro Akihisa ,  Hiroyuki Akazawa

IPC分类号： A61K31/70 ,  A61K31/335 ,  A61K31/05

CPC分类号： C07D313/00 ,  A23L33/10 ,  A23V2002/00 ,  A61K31/05 ,  A61K31/065 ,  A61K31/335 ,  A61K31/7048 ,  A61K36/18 ,  C07H15/24 ,  C07H15/26 ,  C07H17/08 ,  A23V2200/30 ,  A23V2200/312 ,  A23V2250/21 ,  A23V2200/306

摘要： The present invention provides a highly safe pharmaceutical composition for preventing and/or treating bone disease, a pharmaceutical preparation comprising thereof, a health food comprising thereof, a functional food comprising thereof. Since the present invention comprises the arylheptanoid compound shown in the following formula (I) and the derivatives thereof, it enables to prevent and/or treat the bone disease. (In the formula (I), R1 and R5 are a functional group selected from the group consisting of a hydrogen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R2, R3, and R4 are a functional group selected from the group consisting of a hydrogen atom, an oxygen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R5 may be bound on meta-position against heptylene group of another aryl group to form a ring.)

摘要翻译： 本发明提供了用于预防和/或治疗骨疾病的高度安全的药物组合物，包含其的药物制剂，包含其的保健食品，由其组成的功能性食品。 由于本发明包括下式（I）所示的芳基庚类化合物及其衍生物，因此能够预防和/或治疗骨病。 （式（I）中，R 1和R 5为选自氢原子，碳原子数1〜3的烷基，单糖和二糖的官能团; R2，R3，R4为选自 由氢原子，氧原子，碳数为1〜3的烷基，单糖和二糖组成的组; R5可以与另一个芳基的亚庚基的间位结合形成环。）

公开(公告)号：US08729279B2

公开(公告)日：2014-05-20

申请号：US13581975

申请日：2011-02-28

申请人： Je-Tae Woo ,  Ayaka Hibino ,  Takayuki Yonezawa ,  Midori Asai ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai

发明人： Je-Tae Woo ,  Ayaka Hibino ,  Takayuki Yonezawa ,  Midori Asai ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai

IPC分类号： C07D311/00 ,  C07D311/02

CPC分类号： A61K31/353 ,  A61K31/352 ,  C07D311/16 ,  C07D311/18 ,  Y02A50/409

摘要： Agents or pharmaceutical compositions for promoting osteoblast differentiation include purified auraptene or coumarin analogs thereof represented by the following formula 1: wherein R1 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, or a carboxyethyl; R2 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, a carboxyethyl or a coumarinyl; R3 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl or a carboxyethyl; and R4 represents a hydrogen, a C1-C15 liner or branched alkyl, an alkenyl, an alkadienyl or an alkatrienyl.

摘要翻译： 用于促进成骨细胞分化的试剂或药物组合物包括由下式1表示的纯化的紫罗烯或其香豆素类似物：其中R 1表示氢，羟基，甲氧基，甲基，乙基，丙基，羧基，羧甲基或 羧乙基; R 2表示氢，羟基，甲氧基，甲基，乙基，丙基，羧基，羧甲基，羧基乙基或香豆素基; R3表示氢，羟基，甲氧基，甲基，乙基，丙基，羧基，羧甲基或羧基乙基; 并且R 4表示氢，C 1 -C 15内衬或支链烷基，烯基，链二烯基或链亚三烯基。

公开(公告)号：US07803844B2

公开(公告)日：2010-09-28

申请号：US11708041

申请日：2007-02-20

申请人： Kun-Hyung Lee ,  Byung-Yoon Cha ,  Takayuki Yonezawa ,  Shinichi Hasegawa ,  Je-Tae Woo ,  Kazuo Nagai

发明人： Kun-Hyung Lee ,  Byung-Yoon Cha ,  Takayuki Yonezawa ,  Shinichi Hasegawa ,  Je-Tae Woo ,  Kazuo Nagai

IPC分类号： A61K31/05

CPC分类号： A61K31/075 ,  A23L33/10 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/05 ,  A23V2200/306 ,  A23V2250/21

摘要： The present invention provides the pharmaceutical compositions, the pharmaceutical preparations thereof as an active ingredient, the health food, the food with health-promoting benefits and the like. The present invention provides the above-mentioned pharmaceutical preparations and the like comprising at least one of the compound shown in the following formula (I), physiologically acceptable salt thereof, or hydrate thereof. (wherein, R′1, R′2, and R′3 are independently a hydrogen atom, OH, or alkoxy group having C1 to C3, respectively. R1, R2, and R3 are independently a hydrogen atom or alkenyl group having C3 to C5, respectively).

摘要翻译： 本发明提供作为活性成分的药物组合物，其药物制剂，保健食品，具有促进健康益处的食品等。 本发明提供了包含下式（I）所示的化合物，其生理学上可接受的盐或其水合物中的至少一种的上述药物制剂等。 （其中，R'1，R'2和R'3分别是氢原子，OH或具有C1〜C3的烷氧基，R1，R2和R3分别是氢原子或C3〜 C5）。

公开(公告)号：US20100130622A1

公开(公告)日：2010-05-27

申请号：US12275643

申请日：2008-11-21

申请人： Je-Tae WOO ,  Masato Ohta ,  Takayuki Yonezawa ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai

发明人： Je-Tae WOO ,  Masato Ohta ,  Takayuki Yonezawa ,  Toshiaki Teruya ,  Byung-Yoon Cha ,  Kazuo Nagai

IPC分类号： A61K31/05

CPC分类号： A61K31/05

摘要： The present invention provides a pharmaceutical composition for preventing and/or treating periodontal disease comprising at least one having dental root-periodontal tissue formation promotion effect selected from the group consisting of a compound shown in a following formula (I). (In the formula, R1 and R2 are independently functional groups selected from a group consisting of a substituted or non-substituted group of a linear alkyl group, a branched alkyl group, a linear alkenyl group and a branched alkenyl group with having the carbon number of 3 to 5. R′1 and R′2 are independently a hydrogen atom, hydroxyl group, or alkoxy group having the carbon number of 1 to 3.)

摘要翻译： 本发明提供一种用于预防和/或治疗牙周病的药物组合物，其包含至少一种具有选自由下式（I）表示的化合物组成的组中的牙根牙周组织形成促进作用的药物组合物。 （式中，R 1和R 2分别独立地为选自具有碳数的直链烷基，支链烷基，直链烯基和支链烯基的取代或未取代的基团的官能团 R'1和R'2独立地为氢原子，羟基或碳数为1至3的烷氧基。）

公开(公告)号：US20060173069A1

公开(公告)日：2006-08-03

申请号：US10564367

申请日：2004-07-15

申请人： Hiroyuki Osada ,  Kiyotaka Machida ,  Takeshi Shimizu ,  Tadashi Nakata ,  Toshimasa Shinki ,  Je-Tae Woo ,  Kazuo Nagai

发明人： Hiroyuki Osada ,  Kiyotaka Machida ,  Takeshi Shimizu ,  Tadashi Nakata ,  Toshimasa Shinki ,  Je-Tae Woo ,  Kazuo Nagai

IPC分类号： A61K31/695 ,  A61K31/353 ,  C07F7/02

CPC分类号： C07D493/10 ,  Y02P20/55

摘要： The present invention has an object to provide a novel therapeutic agent for hypercalcemia and bone diseases, and a novel compound capable of being used as an active ingredient of the therapeutic agent. The present invention is a therapeutic agent for hypercalcemia or bone diseases, comprising as an active ingredient a reveromycin A derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof. (R represents a hydroxyl-protecting group releasable under acidic conditions.)

摘要翻译： 本发明的目的是提供一种用于高钙血症和骨疾病的新型治疗剂，以及能够用作治疗剂的活性成分的新型化合物。 本发明是高钙血症或骨疾病的治疗剂，其含有作为活性成分的由通式（I）表示的复方霉素A衍生物或其药学上可接受的盐。 （R表示在酸性条件下可释放的羟基保护基）